First Name

Last Name

Age

Email

Please repeat your email

Phone

Institution

Position

—Please choose an option—Primary care physician / GeneralistSpeciality physicianNurseNurse practitionerPharmacistPharma professionalClinical ResearcherStudent (PhD, HCP)FellowResident Medical InternSocial workerOther (please specify)

If you selected "Other", please specify

If you selected "Speciality Physician" or "Resident Medical Intern", please specify your speciality

Average number of HIV patients treated per month, if applicable

Years of dedication to the HIV field

City

Country

Grant request

Travel
—Please choose an option—YesNo

Accommodation
—Please choose an option—YesNo

Motivation

CV

Prior knowledge test

Please, complete the following questionnaire about general HIV Clinical Topics.
This test has a purely informative purpose for the organization of the event. Your answers will not be taken into account when reviewing your candidacy as an attendee and/or fellow.

1. Regarding the pre-exposure prophylaxis (PrEP) with Cabotegravir, the HPTN083 and 084 studies have shown that:
—Please choose an option—A. Resistance never emerges in new HIV infections during Cabotegravir PrEPB. Cabotegravir was superior to oral daily TDF/FTCC. Cabotegravir was administered through an intramuscular injection every 3 monthsD. Rash was significantly more frequent in the Cabotegravir arm

2. Which one of the following is not a recommended regimen in initial ART in the EACS guidelines?
—Please choose an option—A. DTG/3TCB. BIC/FTC/TAFC. DRV/c/FTC/TAFD. TDF/3TC/DOR

3. Regarding hepatic steatosis in PLWH, which one is FALSE?
—Please choose an option—A. Is associated with hepatic fibrosisB. Is frequent in PLWH, involving nearly one of every two PLWHC. Is associated with the metabolic syndromeD. Is not associated with hepatocellular carcinoma

4. Regarding COVID outcomes in PLWH, it is true that:
—Please choose an option—A. A CD4 count < 200 cells has been identified as a risk factor for poorer clinical outcomesB. Vaccine efficacy is virtually the same in people with or without HIV infectionC. Post-acute COVID sequelae are less common in PLWHD. Booster vaccination in PLWH has not shown any reduction in the risk of COVID-19 related hospitalization

5. Regarding the late diagnosis of HIV infection, it is FALSE that:
—Please choose an option—A. Includes any ADIS-defining disease at diagnosis irrespective of the CD4 cell countB. Includes a CD4 cell count <350 cellsC. Is associated with hepatitis B virus infectionD. Is associated with lower overall survival

6. Regarding the epidemiology of the HIV infection in Europe, it is true that:
—Please choose an option—A. Undiagnosed individuals still remain a major concern, mainly in Eastern countriesB. No country in Europe has reached the 3RD 90 (90% of those on ART virally suppressed)C. Most European countries still have a CD4 cell count threshold to initiate ART in PLWHD. The COVID epidemic has had no impact in the provision of PrEP in Europe

I agree to the terms and conditions